HAWTHORNE, N.Y. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (NASDAQ: ACOR) and CMC ICOS Biologics. Inc. today announced that Acorda has selected CMC ICOS as the contract manufacturer for GGF2, the lead molecule in Acorda’s neuregulin program. In preclinical studies, neuregulins have demonstrated potential for neurological protection in a number of indications, including models of MS and stroke. Neuregulins have also shown the potential to reduce and even reverse dysfunction in preclinical models of congestive heart failure by directly strengthening and protecting heart muscle cells.
